Coya Therapeutics, Inc.
COYA
$6.15
$0.172.84%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 2,078.67% | -36.56% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 2,078.67% | -36.56% | |||
| Cost of Revenue | -20.37% | -29.75% | |||
| Gross Profit | 118.50% | 29.39% | |||
| SG&A Expenses | -12.06% | 7.16% | |||
| Depreciation & Amortization | 0.00% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -16.68% | -17.10% | |||
| Operating Income | 70.12% | 16.44% | |||
| Income Before Tax | 65.29% | 16.58% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 65.29% | 16.58% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 65.29% | 16.58% | |||
| EBIT | 70.12% | 16.44% | |||
| EBITDA | 70.19% | 16.46% | |||
| EPS Basic | 65.31% | 16.61% | |||
| Normalized Basic EPS | 73.75% | 16.59% | |||
| EPS Diluted | 65.31% | 16.61% | |||
| Normalized Diluted EPS | 73.75% | 16.59% | |||
| Average Basic Shares Outstanding | 0.05% | 0.03% | |||
| Average Diluted Shares Outstanding | 0.05% | 0.03% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||